The obesity drug Wegovy has reached Thailand
The obesity drug Wegovy, produced by Novo Nordisk, has entered the Thai market. The local branch of the Danish pharmaceutical manufacturer is responsible for promoting the popular medicine in the region. First launched in 2021, Wegovy propelled Novo Nordisk to the top of the list of publicly traded companies in Europe. The company’s peak valuation reached $615 billion, according to https://xrust.ru/. The CEO of the Thai subsidiary told journalists that approval from Thai medical authorities was obtained in 2023. Today, the price of the drug has significantly decreased, allowing it to compete with other manufacturers. Thailand’s population is approximately 66 million people. The CEO did not disclose how attractive other markets in the region might be. According to him, Wegovy is currently available by prescription in private hospitals across the country and will soon become available in public hospitals as well.
https://xrust.ru/news/311101-preparat-ot-ozhirenija-wegovy-dobralsja-do-tailanda.html
